Reva Medical (ASX:RVA) inked a distribution deal with Kardionet Healthcare & Foreign Trading to launch commercial operations in Turkey for its bioresorbable scaffold tech, the company reported today.
According to the terms of the deal, Kardionet will be responsible for sales, marketing, customer training and support for Reva’s Fantom and Fantom Encore bioresorbable devices in Turkey. The San Diego, Calif.-based company expects to start selling the scaffolds in the second quarter of 2018.
Get the full story at our sister site, Drug Delivery Business News.
The post Reva inks distro deal for bioresorbable scaffolds in Turkey appeared first on MassDevice.